CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease;
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months